Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
September 10, 2024 07:00 ET
|
Iterum Therapeutics PLC
FDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Beamr Brings Live Streaming to the Next Level With NVIDIA Holoscan for Media
September 10, 2024 07:00 ET
|
Beamr Imaging Ltd.
Beamr will Demonstrate 4K Live Optimization on NVIDIA Holoscan for Media at IBC 2024 in Amsterdam, the Netherlands, from September 13-16, 2024 Herzliya, Israel, Sept. 10, 2024 (GLOBE...
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
September 10, 2024 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
September 10, 2024 07:00 ET
|
Cibus US LLC
Initial data from Pod Shatter Reduction field trials show promising results The first gene edited trait to complete field trials in oilseed rape in the UK SAN DIEGO, Sept. 10, 2024 (GLOBE...
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024 07:00 ET
|
Mural Oncology, Inc.
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
September 10, 2024 06:57 ET
|
Aclarion, Inc.
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial...
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
September 10, 2024 06:35 ET
|
Silo Pharma, Inc.
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ...
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
September 10, 2024 06:30 ET
|
Roivant Sciences
Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
September 10, 2024 06:30 ET
|
Roivant Sciences
Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for...